drugset / Trial / NCT07589465

Oral Lactulose for Gastrointestinal Recovery After Complex Appendectomy

NCT07589465

Recruiting 150 enrolled Nanchong Central Hospital
RandomizedParallel-groupTriple-blindPrevention

Summary

This is a prospective, triple-blind, placebo-controlled, single-center randomized clinical trial to evaluate the efficacy and safety of early oral lactulose for promoting postoperative gastrointestinal functional recovery in patients undergoing appendectomy for complicated appendicitis. Eligible patients aged ≥18 years with complicated appendicitis confirmed by preoperative SAS 2.0 score, intraoperative findings, or postoperative pathology will be randomly assigned 1:1 to receive oral lactulose or placebo on postoperative day 1 and day 2. The primary outcome is time to GI-2 (time from surgery to the later of first defecation or first tolerance of solid food). Secondary outcomes include time to first flatus, defecation rate within 72 hours, postoperative nausea and vomiting, length of hospital stay, medical costs, postoperative complications, and lactulose-related adverse events. A total of 150 patients will be enrolled. This study aims to provide high-level evidence for optimizing postoperative management in patients with complicated appendicitis.

Timeline

Start
2026-06-21
Primary completion
2029-06-30
Completion
2029-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Lactulose Other / unclassified 20 ml Oral